The medical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to offer a greater substantial decrease in body weight and benefit metabolic marker